(Cilostazol + rosuvastatin) is under clinical development by Korea United Pharm and currently in Phase I for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase I drugs for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Cilostazol + rosuvastatin) LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cilostazol + rosuvastatin) overview
A fixed dose combination of cilostazol and rosuvastatin is under development for the treatment of chronic ischaemic heart disease, coagulation disorders. The drug candidate is an incrementally modified and fixed dose combination drug. It is administered through oral route.
Korea United Pharm overview
Korea United Pharm (KUP) is a pharmaceutical company that produces, markets, sells and distributes pharmaceutical and other healthcare products. It offers incrementally modified drug, anti-cancer, prescription, OTC products, and others. The company provides anti-cancer products such as bleomycin sulfate, carboplatin, cyclophosphamide, dactinomycin and daunorubicin HCl, among others. KUP provides API products such as talniflumate, simvastatin, paroxetine and carvedilol. The company offers prescription products such as iohexol, arginine thiazolidine carboxylate, domperidone maleate, adefovir dipivoxil, entecavir, trimebutine maleate and omeprazole enteric granule, among others. Its products are used in the therapeutic areas of gastrointestinal, cardiovascular, hematopoietic, respiratory, central nervous system, musculoskeletal, endocrine and metabolic and other disorders. The company operates through its branch offices located in the Philippines, Vietnam, Myanmar, China and others. KUP is headquartered in Sejong, South Korea.
For a complete picture of (Cilostazol + rosuvastatin)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
